Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 18Terminated 2Recruiting 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 93Lung Neoplasms 35Meningeal Carcinomatosis 11Neoplasms 10Neoplasm Metastasis 8Colorectal Neoplasms 6Adenocarcinoma of Lung 6Parkinson Disease 4, Autosomal Dominant Lewy Body 4Mesothelioma, Malignant 4Non-squamous Non-small Cell Lung Cancer 3NSCLC 3Mesothelioma 3Carcinoma 3Advanced Solid Tumors 3Pancreatic Neoplasms 2Non Squamous Non Small Cell Lung Cancer 2Neoplasms by Site 2Neoplasms by Histologic Type 2Endometrial Neoplasms 2Carcinoma, Bronchogenic 2Bronchial Neoplasms 2Breast Neoplasms 2Vaccinia 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Small Cell Lung Carcinoma 1Sexual Dysfunction, Physiological 1

Interventions

Fulvestrant 60Capecitabine 47Trastuzumab 46Letrozole 45pembrolizumab 42Carboplatin 41Paclitaxel 39Cyclophosphamide 38ribociclib 37abemaciclib 36pertuzumab 34Blood Specimen Collection 31Specimen Handling 28trastuzumab deruxtecan 27Surveys and Questionnaires 26Docetaxel 26Tamoxifen 25Anastrozole 25exemestane 24palbociclib 21130-nm albumin-bound paclitaxel 21Magnetic Resonance Spectroscopy 20Biopsy 19sacituzumab govitecan 18eribulin 18Radiotherapy 18Gemcitabine 18olaparib 17Injections 17Epirubicin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Breast Neoplasms × Pemetrexed × Clear all
NCT06462092 2025-09-29

Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer

Guangzhou Medical University

Phase 1/2 Recruiting
34 enrolled
BreastCNS

Breast Neoplasms, Meningeal Carcinomatosis

NCT05315700 2025-08-05

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

ORIC Pharmaceuticals

Phase 1/2 Recruiting
350 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡